Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors

• Published in: Current cardiology reports 2023-09, Vol.25 (9), p.941-958
• Main Authors: Aghel, Nazanin, Baro Vila, Rocio C., Lui, Michelle, Hillis, Christopher, Leong, Darryl P.
• Format: Article
• Language: English
• Subjects: Atrial Fibrillation - drug therapy; Cardio-Oncology (LA Baldassarre; Cardiology; Cardiovascular System; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - chemically induced; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Medicine; Medicine & Public Health; Protein Kinase Inhibitors - adverse effects; Section Editor; Topical Collection on Cardio-Oncology; Tyrosine Kinase Inhibitors
• ISSN: 1523-3782; 1534-3170
• DOI: 10.1007/s11886-023-01916-4

Purpose of Review Bruton's tyrosine kinase inhibitors (BTKis) have changed the treatment and prognosis of several B-cell malignancies. However, since the approval of the first BTKi, ibrutinib, reports of cardiovascular adverse events especially atrial fibrillation have arisen. In this review, we discuss the cardiovascular side effects of BTKis and the management of these toxicities in clinical practice. Recent Findings BTKIs increase the risks of atrial fibrillation, bleeding, hypertension, heart failure, and potentially ventricular arrhythmia. Newer second and third-generation BTKis appear to have a lower risk of cardiovascular adverse events; however, long-term follow-up data are not available for these new BTKis. Summary BTKis are an effective treatment for some B-cell malignancies; however, they can cause cardiovascular side effects. The best preventive strategies to minimize cardiovascular complications remain undefined. Currently, a practical approach for managing patients receiving BTKis includes the management of cardiovascular risk factors and side effects of BTKis to prevent interruption of cancer treatment.